The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms
about
Review on genetic variants and maternal smoking in the etiology of oral clefts and other birth defectsA framework for assessing risks to children from exposure to environmental agents.Inherited disorders of bilirubin clearanceDevelopmental pharmacokinetics in pediatric populationsPersistent pharmacokinetic challenges to pediatric drug developmentSulphate in pregnancyThe epidemiology of hepatoblastomaDevelopmental expression of aldehyde dehydrogenase in rat: a comparison of liver and lung developmentGene expression profiling reveals a regulatory role for ROR alpha and ROR gamma in phase I and phase II metabolismPolymorphisms of genes involved in polycyclic aromatic hydrocarbons' biotransformation and atherosclerosisDetoxiProt: an integrated database for detoxification proteinsClinical pharmacology in the adolescent oncology patient.Human milk biomonitoring data: interpretation and risk assessment issues.Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system.Enterohepatic recirculation of bioactive ginger phytochemicals is associated with enhanced tumor growth-inhibitory activity of ginger extract.Genetic variation in the 3'-UTR of CYP1A2, CYP2B6, CYP2D6, CYP3A4, NR1I2, and UGT2B7: potential effects on regulation by microRNA and pharmacogenomics relevance.Acetaminophen elimination half-life in humans is unaffected by short-term consumption of sulfur amino acid-free diet.Oxidation of plasma cysteine/cystine and GSH/GSSG redox potentials by acetaminophen and sulfur amino acid insufficiency in humansValproic acid pathway: pharmacokinetics and pharmacodynamics.Prenatal and perinatal analgesic exposure and autism: an ecological linkPregnane X receptor and drug-induced liver injury.Biochemical effects of ozone on asthma during postnatal developmentDevelopmental and pediatric pharmacogenomics.Paediatric pharmacokinetics: key considerations.Early Life Metabolism of Bisphenol A: A Systematic Review of the LiteratureInterferon-gamma plays protective roles in sodium arsenite-induced renal injury by up-regulating intrarenal multidrug resistance-associated protein 1 expression.Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents.Serial Free Bisphenol A and Bisphenol A Glucuronide Concentrations in Neonates.Age-Related Changes in MicroRNA Expression and Pharmacogenes in Human LiverRNA-Seq reveals common and unique PXR- and CAR-target gene signatures in the mouse liver transcriptome.Computational pharmacokinetics during developmental windows of susceptibility.Pharmacotherapy of pediatric HIV infectionMode of action: neurotoxicity induced by thyroid hormone disruption during development--hearing loss resulting from exposure to PHAHs.Patterns of drug utilization in a neonatal intensive care unit.Developmental toxicity of dextromethorphan in zebrafish embryos/larvae.Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations.Developmental and tissue-specific expression of human flavin-containing monooxygenases 1 and 3.Cell-based models to study hepatic drug metabolism and enzyme induction in humans.Fetal liver bisphenol A concentrations and biotransformation gene expression reveal variable exposure and altered capacity for metabolism in humans.Role of CAR and PXR in xenobiotic sensing and metabolism.
P2860
Q24650568-70CB3330-650A-49E7-B4CA-BE7B7929B4E1Q24811017-A7A810C9-6243-4D3D-A0F0-FAF427EA5F60Q26776470-51802998-CA0A-4978-82D4-A7765C5FBE43Q27002933-AFDAA9D0-7F84-4FAC-A550-3D0C9CD3E127Q27023912-438DC25C-9D53-494D-946F-2386DEE8C434Q28083379-5913ED9D-B529-4031-8224-2C50E78813CAQ28268711-F8425DAC-75F3-428C-88AC-D4181048FE25Q28564424-DD7CAB41-12E7-4F5E-A49C-DF6A500D4A5DQ28594055-AD503EE6-54DB-43E1-BA62-5F18CA6148DDQ28660221-A2666202-0C9D-406A-AAE1-A18954638903Q30427279-87B1FE03-43C4-4237-B6CD-2630CBE1102AQ30497854-87E4FC28-0E8B-4737-A476-69C40CEAAF8AQ31006357-43BA8E0A-10A1-4F1F-9048-BF93DBBBA44BQ33451969-D6C97182-7D29-4CAC-8804-38FD1BE81C2CQ33705263-36D4234A-AF25-4DE3-AD46-2E15CDA68904Q33708471-27302F39-84E1-4465-B013-BD17B0A57EAAQ33890856-DF0C086C-D5AA-4DE5-A9E7-D0E5DCE67CF5Q33890898-F5BAB57F-747D-44DF-AB2F-FD0584EFB19FQ34327652-3D2DAE43-B546-4EF3-A941-A1F92BDCC37CQ34343570-FD42F921-D4A3-464D-8E6D-7DE3CE376F72Q34345049-8B069581-EBF7-49CF-914E-1DDF9BAB626DQ35019446-70225CCE-F803-48E0-ADCE-2C8AAAB08458Q35116112-12557745-6AB6-4868-A01E-62AAEAE470DDQ35135940-ED923965-A719-43A1-978D-AA0E2F7C3D9CQ35234895-441ECDCD-BADF-4386-BBED-49B4FDC89C2DQ35607239-BD9559B0-61F6-495A-95A3-3B0B7A84121DQ35624622-C9E74E5E-ED08-4013-9A66-BAFF543520CCQ35799755-E1099D40-2DCC-49BE-BE38-784970FD7403Q35883284-8CBE665C-0D39-48E1-8A6E-85F9439374A4Q35998854-BBDCDF5C-E888-4E79-B26A-818BEFD4CF2DQ36195215-B6E22323-BC0B-459D-81E5-3CB0150DDF40Q36301325-FAE67E5D-0675-465C-8CA9-4647C5ADCC44Q36370372-D730BAE9-118E-4352-BB12-347D857B652CQ36428827-A033A2FF-558C-472F-87F9-F6BC10C64C82Q36449529-C0B5C35B-95CD-4D59-9B8C-D8A8DA9D7A6EQ36544972-162451C5-3853-49FE-BB0A-369DB93517CEQ36545025-3ED686C3-B128-4B58-A932-FDB064924B55Q36572634-1A07DD28-577C-44F7-9921-9850B8411168Q36625649-7ABECDCD-BA9A-4016-9CA0-D6660F7C3D5CQ36672089-D1565A02-B782-4A6F-96C5-174961F43E6C
P2860
The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms
description
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2002
@ast
im Februar 2002 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2002/02/01)
@sk
vědecký článek publikovaný v roce 2002
@cs
wetenschappelijk artikel (gepubliceerd op 2002/02/01)
@nl
наукова стаття, опублікована в лютому 2002
@uk
مقالة علمية (نشرت في فبراير 2002)
@ar
name
The ontogeny of human drug-met ...... ymes and regulatory mechanisms
@ast
The ontogeny of human drug-met ...... ymes and regulatory mechanisms
@en
The ontogeny of human drug-met ...... ymes and regulatory mechanisms
@nl
type
label
The ontogeny of human drug-met ...... ymes and regulatory mechanisms
@ast
The ontogeny of human drug-met ...... ymes and regulatory mechanisms
@en
The ontogeny of human drug-met ...... ymes and regulatory mechanisms
@nl
prefLabel
The ontogeny of human drug-met ...... ymes and regulatory mechanisms
@ast
The ontogeny of human drug-met ...... ymes and regulatory mechanisms
@en
The ontogeny of human drug-met ...... ymes and regulatory mechanisms
@nl
P356
P1476
The ontogeny of human drug-met ...... ymes and regulatory mechanisms
@en
P2093
D. Gail McCarver
Ronald N. Hines
P304
P356
10.1124/JPET.300.2.361
P407
P577
2002-02-01T00:00:00Z